CD274 and melanoma: In melanoma patients, higher pretreatment levels of circulating ExoPD-L1 were negatively correlated with disease responses to immunotherapy, and, moreover, were linked to poorer clinical outcomes, supporting the critical impact of ExoPD-L1 in therapeutic resistance to anti-PD-L1 antibody treatment.